CRH, corticotropin releasing hormone, 1392

N. diseases: 402; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 Biomarker disease BEFREE In this review, we summarize the key evidence for and against the involvement of stress-associated modulation of the CRF system in the pathogenesis of Alzheimer's disease and discuss how recent findings could lead to new potential treatment possibilities in Alzheimer's disease by using CRF-BP as a therapeutic target. 31641098 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 Biomarker disease BEFREE Microglia express receptor for CRH that mediate neurodegeneration in AD. 30837843 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 Biomarker disease BEFREE Sex differences are evident in the neurochemical, morphological and molecular regulation of LC neurons by CRF, providing a compelling basis for the higher prevalence of stress-related disorders such as AD in females. 31250157 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 Biomarker disease BEFREE In recent years, a substantial amount of research has been done investigating a key stress-response mediator, corticotropin-releasing hormone (CRH), and its interactions with AD relevant processes. 28633663 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 Biomarker disease BEFREE Our results also provide evidence for the involvement of the CRF system in noise-induced AD-like neurodegeneration. 29228900 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 AlteredExpression disease BEFREE Phosphoproteomic results were validated by demonstrating that CRF overexpression in females was associated with increased tau phosphorylation and, in a mouse model of AD pathology, phosphorylation of β-secretase, the enzyme involved in the formation of amyloid β. 27752081 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 Biomarker disease BEFREE Stress and corticotropin-releasing factor (CRF) have been implicated as mechanistically involved in Alzheimer's disease (AD), but agents that impact CRF signaling have not been carefully tested for therapeutic efficacy or long-term safety in animal models. 26555315 2016
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 AlteredExpression disease BEFREE In particular, the major stress receptor, CRF receptor type 1 (CRFR1), modulates cellular activity in many AD-relevant brain areas, and has been demonstrated to impact both tau phosphorylation and amyloid-β (Aβ) pathways. 25697705 2015
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 AlteredExpression disease BEFREE Furthermore, in a knockin mouse model of AD that expresses familial AD (FAD) mutations of both APP with humanized amyloid beta (hAβ), and presenilin 1 (PS1), in their endogenous patterns (APP/hAβ/PS1 animals), corticotropin releasing factor (CRF) levels are increased in key stress-related nuclei, resting corticosteroid levels are elevated, and animals display increased anxiety-related behavior. 22336193 2012
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.390 Therapeutic disease CTD_human Here we show that ligands that dissociate CRF from CRF-BP increase brain levels of 'free CRF' in AD to control levels and show cognition-enhancing properties in models of learning and memory in animals without the characteristic stress effects of CRF receptor agonists. 7477348 1995